skinny.

Latest / Stock Movers

GSK Jumps, Astrazeneca Up

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- GSK announced that its Jideytro (zidesamtinib) achieved a 94% objective response rate in TKI-naïve ROS1-positive non-small cell lung cancer patients in the registrational phase I/II ARROS-1 trial, with no placebo comparator.

- AstraZeneca’s breast-cancer pill trial failure could cut several billion dollars from the drug’s potential sales, according to analysts.

See omnystudio.com/listener for privacy information.

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.